Epigral 배당 및 자사주 매입
배당 기준 점검 3/6
Epigral 수익으로 충분히 충당되는 현재 수익률 0.39% 보유한 배당금 지급 회사입니다. 다음 지급일은 8th July, 2026 이며 배당락일은 다음과 같습니다. 1st June, 2026.
핵심 정보
0.4%
배당 수익률
-6.1%
자사주 매입 수익률
| 총 주주 수익률 | -5.7% |
| 미래 배당 수익률 | 0.5% |
| 배당 성장률 | n/a |
| 다음 배당 지급일 | 08 Jul 26 |
| 배당락일 | 01 Jun 26 |
| 주당 배당금 | n/a |
| 배당 성향 | 6% |
최근 배당 및 자사주 매입 업데이트
Recent updates
분석 기사 • May 08
Epigral Limited's (NSE:EPIGRAL) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Celebrations may be in order for Epigral Limited ( NSE:EPIGRAL ) shareholders, with the covering analyst delivering a...
내러티브 업데이트 • Apr 21
EPIGRAL: Steady ₹2,000 View Ahead Of 2026 Postal Ballot Outcome
Epigral's analyst fair value estimate is maintained at ₹2,000, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, as analysts fine tune their model inputs rather than changing their core view on the stock. What's in the News Epigral has scheduled a Special or Extraordinary Shareholders Meeting on May 19, 2026, to be conducted via postal ballot in India (Key Developments).내러티브 업데이트 • Apr 06
EPIGRAL: Steady ₹2,000 View Will Await Q3 Board Outcome
Analysts now keep Epigral's fair value estimate broadly unchanged at about ₹2,000 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions. This signals a largely steady view on the stock's valuation drivers.내러티브 업데이트 • Mar 23
EPIGRAL: Steady ₹2,000 Outlook Will Anticipate Q3 Board Meeting Outcome
Analysts have kept Epigral's fair value estimate steady at ₹2,000, with only minor tweaks to the discount rate, revenue growth, profit margin assumptions and future P/E supporting an unchanged price target. What's in the News A board meeting is scheduled on January 30, 2026 to consider the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report.내러티브 업데이트 • Mar 08
EPIGRAL: Steady ₹2,000 Fair Value Will Anticipate Q3 Board Review Outcome
Analysts have kept Epigral’s fair value estimate steady at ₹2,000, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects fine tuning of their models rather than a material change in conviction.내러티브 업데이트 • Feb 21
EPIGRAL: Reaffirmed ₹2,000 Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000. A slightly lower assumed future P/E and a marginally higher discount rate together support this unchanged price target.내러티브 업데이트 • Feb 07
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts now see fair value for Epigral at ₹2,000.00 per share, with the unchanged target based on updated assumptions on discount rate, revenue growth, profit margin and future P/E that together reflect a recalibration of their long term earnings and valuation framework. What's in the News A board meeting is scheduled on January 30, 2026 to consider unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report from statutory auditors (company filing).내러티브 업데이트 • Jan 24
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000 after updating their assumptions for discount rate, revenue growth, profit margin and future P/E. These revisions support a recalibrated price target narrative rather than a change in the overall valuation direction.내러티브 업데이트 • Jan 09
EPIGRAL: New CFO Appointment Is Expected To Strengthen Future Financial Governance
Analysts have cut their price target on Epigral from ₹2,600 to ₹2,000, citing updated assumptions that combine slightly higher revenue growth and profit margins with a lower future P/E multiple. What's in the News Epigral appointed Mr. Rakesh Agrawal as Chief Financial Officer and Key Managerial Personnel, effective 10 November 2025, following a board decision based on the Nomination and Remuneration Committee's recommendation (Key Developments).분석 기사 • Dec 26
Returns On Capital At Epigral (NSE:EPIGRAL) Have Hit The Brakes
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...분석 기사 • Nov 16
Downgrade: What You Need To Know About The Latest Epigral Limited (NSE:EPIGRAL) Forecasts
Market forces rained on the parade of Epigral Limited ( NSE:EPIGRAL ) shareholders today, when the covering analyst...분석 기사 • Nov 13
Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models
Epigral Limited ( NSE:EPIGRAL ) shareholders are probably feeling a little disappointed, since its shares fell 9.0% to...분석 기사 • Nov 11
If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...분석 기사 • Sep 28
Epigral (NSE:EPIGRAL) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...내러티브 업데이트 • Aug 06
Capacity Expansion And Green Energy Will Unlock Global Opportunities
The increase in Epigral’s consensus analyst price target to ₹2600 primarily reflects higher anticipated future earnings multiples, as indicated by the rise in future P/E, while the discount rate remains stable. What's in the News Upcoming board meeting to consider un-audited Q1 FY26 results and review fund-raising proposals via debt instruments.분석 기사 • Aug 06
Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next
NSEI:EPIGRAL 1 Year Share Price vs Fair Value Explore Epigral's Fair Values from the Community and select yours As you...분석 기사 • Jul 30
Epigral Limited (NSE:EPIGRAL) Might Not Be As Mispriced As It Looks
With a price-to-earnings (or "P/E") ratio of 23.6x Epigral Limited ( NSE:EPIGRAL ) may be sending bullish signals at...분석 기사 • Jun 02
Investors Should Be Encouraged By Epigral's (NSE:EPIGRAL) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...분석 기사 • Apr 03
Subdued Growth No Barrier To Epigral Limited (NSE:EPIGRAL) With Shares Advancing 25%
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Feb 28
Calculating The Fair Value Of Epigral Limited (NSE:EPIGRAL)
Key Insights Epigral's estimated fair value is ₹1,644 based on 2 Stage Free Cash Flow to Equity With ₹1,630 share...
새로운 내러티브 • Jan 16
Doubling CPVC And ECH Production Will Strengthen Future Prospects
Epigral is expanding production capacity and focusing on high-margin value-added products to enhance earnings and future growth.분석 기사 • Dec 18
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Jul 04
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Apr 19
Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump
The Epigral Limited ( NSE:EPIGRAL ) share price has done very well over the last month, posting an excellent gain of...분석 기사 • Feb 23
Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Epigral Limited ( NSE:EPIGRAL ) shares have been powering on, with a gain of 28% in the...분석 기사 • Feb 21
Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...분석 기사 • Apr 05
Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...분석 기사 • Sep 28
With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...예정된 배당 지급
지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: EPIGRAL 10년 미만 동안 배당금을 지급해 왔으며 이 기간 동안 지급액은 휘발성이었습니다.
배당금 증가: EPIGRAL 3 년 동안만 배당금을 지급해 왔으며 그 이후로 지급액이 증가하지 않았습니다.
배당 수익률 vs 시장
| Epigral 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (EPIGRAL) | 0.4% |
| 시장 하위 25% (IN) | 0.3% |
| 시장 상위 25% (IN) | 1.5% |
| 업계 평균 (Chemicals) | 0.8% |
| 분석가 예측 (EPIGRAL) (최대 3년) | 0.5% |
주목할만한 배당금: EPIGRAL 의 배당금( 0.39% )은 Indian 시장에서 배당금 지급자의 하위 25%( 0.3% )보다 높습니다.
고배당: EPIGRAL 의 배당금( 0.39% )은 Indian 시장에서 배당금 지급자의 상위 25%( 1.5% )와 비교해 낮습니다.
주주 대상 이익 배당
수익 보장: 낮은 배당금 지급 비율 (6.5%)로 인해 EPIGRAL의 배당금 지급은 수익으로 충분히 충당됩니다.
주주 현금 배당
현금 흐름 범위: 합리적인 현금 지급 비율 ( 52.1% )로 EPIGRAL 의 배당금 지급은 현금 흐름으로 충당됩니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 02:01 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Epigral Limited는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | BP Wealth Management Private Limited |
| null null | Emkay Global Financial Services Ltd. |
| Meet Vora | Emkay Global Financial Services Ltd. |